TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9419773

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg every 4 hours for 48 hours postpartum)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Uterine curettage (immediate following delivery)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard therapy (intravenous magnesium sulfate 2 g/hour)
Number of subjects: 45
Study: 2845461

Group type: EXPERIMENTAL
Intervention: Theophylline infusion (mean = 14.0 micrograms/ml) in normal saline (308 mEq)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (350 mEq in normal saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (308 mEq)
Number of subjects: 10
Study: 4206451

Group type: EXPERIMENTAL
Intervention: Serogroup A meningococcal polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetanus toxoid (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated contrast group
Number of subjects: 0
Study: 31902066

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study: 30092646

Group type: EXPERIMENTAL
Intervention: Personalized environmental report back
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (no personalized report back)
Number of subjects: 560
Study: 28429078

Group type: EXPERIMENTAL
Intervention: Telephone coaching for depression
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Control group (no telephone coaching)
Number of subjects: 1586
Study: 26242220

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg (two 150 mg tablets) administered in fed state
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olaparib 300 mg (two 150 mg tablets) administered in fasted state
Number of subjects: 60
Study: 23933029

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 12
Study: 21266699

Group type: COMPARATOR
Intervention: Soy oil-based fat emulsion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Olive oil-based fat emulsion
Number of subjects: 22
Study: 19187817

Group type: EXPERIMENTAL
Intervention: Exposure with oppositional actions (E+OA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Exposure only (EO)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pulsed audio‐photic stimulation (APS)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 88
Study: 16769267

Group type: EXPERIMENTAL
Intervention: Dai‐kenchu‐to (15 g/d)
Number of subjects: 17
Study: 14732896

Group type: COMPARATOR
Intervention: Antituberculous treatment (Isoniazid, Rifampicin, Pyrazinamid, and Streptomycin) alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Antituberculous treatment plus additional pleural tapping for four weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (0.75 mg/kg body weight) tapered over four weeks (for both groups in phase II)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lung function tests by spirometry (for both groups)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Radiological changes (for both groups)
Number of subjects: 32
Study: 10916329

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n = 51), chewed three times daily for a minimum of five minutes each time for three months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Sorbitol gum (placebo group, n = 50)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No gum (control group, n = 50)
Number of subjects: 151
Study: 8645022

Group type: EXPERIMENTAL
Intervention: 1/2 FAM (5-FU 200 mg/m2/day IV, ADM 15 mg/m2/day IV, MMC 5 mg/m2/day IV)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (palliative treatment alone)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 1/2 FAM
Number of subjects: 83
Study: 1449142

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 3931363

Group type: EXPERIMENTAL
Intervention: 0.8 mg glycerol trinitrate
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no glycerol trinitrate)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 0.8 mg glycerol trinitrate after aortocoronary venous bypass
Number of subjects: 69
Study: 29331916

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 28616088

Group type: EXPERIMENTAL
Intervention: Novafen administration before periodontal surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 24969635

Group type: EXPERIMENTAL
Intervention: Midodrine (7.5-22.5 mg max) followed by penile vibratory stimulation (PVS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-midodrine (placebo) followed by penile vibratory stimulation (PVS)
Number of subjects: 20
Study: 23936895

Group type: EXPERIMENTAL
Intervention: MSN (morphine sulfate and naltrexone hydrochloride extended‐release)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS (controlled‐release morphine sulfate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MS
Number of subjects: 0
Study: 20484613

Group type: EXPERIMENTAL
Intervention: Exenatide (10 µg) administered at -60 minutes, -30 minutes, or -15 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exenatide (10 µg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered at -30 minutes
Number of subjects: 20
Study: 18160497

Group type: EXPERIMENTAL
Intervention: High flexion NexGen total knee replacement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard NexGen total knee replacement
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison between high flexion and standard designs
Number of subjects: 56
Study: 16611394

Group type: EXPERIMENTAL
Intervention: Parents-only intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Parents and children together intervention
Number of subjects: 32
Study: 12589865

Group type: EXPERIMENTAL
Intervention: Chronologically structured self‐completion questionnaire
Number of subjects: 259

Group type: COMPARATOR
Intervention: Traditionally structured self‐completion questionnaire
Number of subjects: 259
Study: 10512913

Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: heparin
Number of subjects: 0
Study: 7560237

Group type: EXPERIMENTAL
Intervention: Chlorhexidine toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 20
Study: 1940256

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 7018305

Group type: EXPERIMENTAL
Intervention: Lithium therapy for 3 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lithium therapy for 3 months in depressed patients
Number of subjects: 47
Study: 31500510

Group type: EXPERIMENTAL
Intervention: VIPP-SD (Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 66
Study: 30970436

Group type: EXPERIMENTAL
Intervention: Etomidate/midazolam
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol/midazolam
Number of subjects: 200
Study: 28436305

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control (no intra-arterial treatment)
Number of subjects: 500
Study: 24823763

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chloral hydrate (CH)
Number of subjects: 17
Study: 24461317

Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs) during glucose loading
Number of subjects: 0
Study: 22962203

Group type: EXPERIMENTAL
Intervention: Tier 1 Program of Project P.A.T.H.S.
Number of subjects: 216
Study: 19390750

Group type: EXPERIMENTAL
Intervention: 400 IU/d cholecalciferol
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 1200 IU/d cholecalciferol
Number of subjects: 218

Group type: COMPARATOR
Intervention: 0 IU/d cholecalciferol (placebo)
Number of subjects: 218
Study: 17720256

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.025% and lignocain 2%
Number of subjects: 53

Group type: COMPARATOR
Intervention: Oxymetazoline 0.025% alone
Number of subjects: 53
Study: 15228999

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension
Number of subjects: 128
Study: 11785439

Group type: EXPERIMENTAL
Intervention: FemoStop device
Number of subjects: 212

Group type: COMPARATOR
Intervention: Manual pressure
Number of subjects: 212
Study: 9641433

Group type: EXPERIMENTAL
Intervention: Topical diclofenac PLO (2% diclofenac)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo PLO (no diclofenac)
Number of subjects: 14
Study: 9215651

Group type: EXPERIMENTAL
Intervention: SEDDS formulation (1125 mg twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Elixir (750 mg three times daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SEDDS formulation (750 mg three times daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both SEDDS regimens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Twice-daily administration
Number of subjects: 49
Study: 1764872

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate and Placebo (in unknown order)
Number of subjects: 0
Study: 6276278

Group type: EXPERIMENTAL
Intervention: New, specially prepared swelling substances administered at the recommended doses
Number of subjects: 20
Study: 30583772

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 188

Group type: COMPARATOR
Intervention: No tourniquet (Control)
Number of subjects: 188
Study: 27983733

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine drink
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 50
Study: 25572345

Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cocaine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 23598607

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medical therapy alone (Control)
Number of subjects: 40
Study: 21204677

Group type: EXPERIMENTAL
Intervention: Web-based intervention involving 7 theory-based learning lessons
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group receiving minimal physical activity information
Number of subjects: 104
Study: 18289194

Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 612

Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment (esomeprazole 40 mg od for reflux esophagitis, esomeprazole 20 mg od for no esophagitis) for 4 weeks
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Number of subjects: 612

Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment with esomeprazole 20 mg od maintenance treatment after 4 weeks
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Empirical treatment with esomeprazole
Number of subjects: 612

Group type: COMPARATOR
Intervention: Endoscopy-oriented treatment
Number of subjects: 612
Study: 17052416

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg in 2mls)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo, 2 mls)
Number of subjects: 60
Study: 14983991

Group type: EXPERIMENTAL
Intervention: Nurse-administered protocol (NP)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Traditional physician reminder (PR)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Both NP and PR groups
Number of subjects: 473
Study: 10851773

Group type: EXPERIMENTAL
Intervention: Gentian violet topical application
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study: 8656090

Group type: EXPERIMENTAL
Intervention: CHIVA
Number of subjects: 148

Group type: COMPARATOR
Intervention: stripping
Number of subjects: 148
Study: 1905472

Group type: EXPERIMENTAL
Intervention: Low protein diet of high biological value (20-30 g/day) and high calorie content (3000 kcal/day) for 18 to 28 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unrestricted protein intake (40-60 g/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Linear regression analysis of serum creatinine values against time
Number of subjects: 12
Study: 6140023

Group type: EXPERIMENTAL
Intervention: Fazadinium 0.75, 1.0, 1.25 mg kg‐1
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fazadinium and Pancuronium
Number of subjects: 64
Study: 30918032

Group type: EXPERIMENTAL
Intervention: mupirocin plus aFGF
Number of subjects: 120

Group type: COMPARATOR
Intervention: mupirocin plus placebo
Number of subjects: 120
Study: 30113199

Group type: EXPERIMENTAL
Intervention: Comprehensive care model featuring psychological and physical interventions
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Fluctuating higher-risk group
Number of subjects: 179
Study: 27734772

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 8.75 mg lozenges
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 204
Study: 24714767

Group type: EXPERIMENTAL
Intervention: Aromatic white spirits (aWS) at 100 mg/m(3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aromatic white spirits (aWS) at 300 mg/m(3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dearomatized white spirits (daWS) at 100 mg/m(3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dearomatized white spirits (daWS) at 300 mg/m(3)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 12
Study: 22259068

Group type: EXPERIMENTAL
Intervention: Oncologists with more information resources
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Oncologists with a sense of responsibility to discuss fertility issues
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Gynecologic oncologists
Number of subjects: 344

Group type: COMPARATOR
Intervention: Physician age, gender, and practice setting
Number of subjects: 344
Study: 19062091

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (600-800 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower-dose (intermittent or pulsed) maintenance therapy
Number of subjects: 0
Study: 17932364

Group type: EXPERIMENTAL
Intervention: Low-fat/low-glycemic load diet (<20% energy from fat and total daily glycemic load <100)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard American diet (approximately 35% energy from fat and total daily glycemic load >200)
Number of subjects: 8
Study: 15534356

Group type: EXPERIMENTAL
Intervention: Cytarabine and daunorubicin (AD)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Cytarabine and escalated doses of daunorubicin and etoposide +/- PSC-833 (ADE/ADEP)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: One cycle of high-dose cytarabine (HDAC) followed by etoposide/cyclophosphamide and mitoxantrone/diaziquone (group I)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Three HDAC cycles (group II)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Four intermediate-dose cytarabine (IDAC) or HDAC cycles (group III)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: One HDAC/etoposide cycle and autologous stem-cell transplantation (ASCT; group IV)
Number of subjects: 490
Study: 11965510

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron supplementation (4800 RE vitamin A, 120 mg iron, and 500 microg folic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron supplementation (120 mg iron and 500 microg folic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron supplementation
Number of subjects: 0
Study: 9808874

Group type: EXPERIMENTAL
Intervention: Ethylephrine 75 mg/die
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/die
Number of subjects: 169

Group type: COMPARATOR
Intervention: No treatment (Control Group A)
Number of subjects: 169
Study: 8620236

Group type: EXPERIMENTAL
Intervention: Educational intervention on pediatric health care issues
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual PED discharge instructions (Control)
Number of subjects: 130
Study: 2674593

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1) administered 60 min prior to exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1)
Number of subjects: 6
Study: 807952

Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate followed by radical irradiation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 96
Study: 30112756

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4) in males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal magnesium sulfate (MgSO4) in females
Number of subjects: 0
Study: 28141698

Group type: EXPERIMENTAL
Intervention: RV5mp
Number of subjects: 1014

Group type: COMPARATOR
Intervention: RV5
Number of subjects: 1014
Study: 25402222

Group type: EXPERIMENTAL
Intervention: Work-related cognitive-behavioral treatment (W-CBT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment as usual (CBT-AU)
Number of subjects: 26
Study: 24432676

Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to SSRIs
Number of subjects: 60

Group type: COMPARATOR
Intervention: SSRIs only (Control)
Number of subjects: 60
Study: 21503375

Group type: EXPERIMENTAL
Intervention: Educational intervention on obesity
Number of subjects: 300

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 300
Study: 19386609

Group type: COMPARATOR
Intervention: Terlipressin infusion alone for 5 days
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Banding ligation plus terlipressin infusion for 2 days
Number of subjects: 93
Study: 16878187

Group type: EXPERIMENTAL
Intervention: Granisetron (50 microg/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Metoclopramide (2 mg/kg) plus dimenhydrinate (5 mg/kg)
Number of subjects: 26
Study: 15107313

Group type: EXPERIMENTAL
Intervention: Focused educational programme on nutrition over one school year
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 644
Study: 11736727

Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based therapy (10 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 3-day rabeprazole-based therapy (20 mg rabeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 7-day omeprazole-based therapy (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin, all twice daily)
Number of subjects: 173
Study: 9414057

Group type: EXPERIMENTAL
Intervention: Pain Education Program
Number of subjects: 313
Study: 8214728

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol (BU) 3 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Epidural morphine (MS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine (NB) 10 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral naltrexone (NX) 6 mg
Number of subjects: 102
Study: 3101895

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study: 31490239

Group type: EXPERIMENTAL
Intervention: Circumferential negative pressure (125 mm Hg) applied to the midarm for 9 hours
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control: Same device without negative pressure applied to the contralateral midarm
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both intervention and control
Number of subjects: 13
Study: 29716655

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg once daily for the first 6 weeks, then 10 mg once daily for the next 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 18
Study: 29278472

Group type: EXPERIMENTAL
Intervention: MV+QL
Number of subjects: 60

Group type: COMPARATOR
Intervention: MV
Number of subjects: 60
Study: 24403544

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine booster
Number of subjects: 250

Group type: COMPARATOR
Intervention: No Hib conjugate vaccine booster
Number of subjects: 250
Study: 22405683

Group type: EXPERIMENTAL
Intervention: Acupuncture (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo acupuncture (n = 20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 41
Study: 20595196

Group type: EXPERIMENTAL
Intervention: Mechanomyography
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acceleromyography
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normalization during recovery
Number of subjects: 40